Cartesian Therapeutics develops mRNA-based cell therapies for autoimmune diseases, starting with its lead candidate for myasthenia gravis. It last closed at $6.14 on Nov 20, up 4.24% on the day. The next earnings report for RNAC is expected around Mon, Mar 8, 2027. For the quarter ended Sep 2026, RNAC reported EPS of -$0.38 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 7.1% the session after earnings. Over the last 12 months RNAC insiders bought $206K of stock on the open market and sold $259K, according to SEC Form 4 filings.
AI Auto Pilots
Is RNAC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RNAC.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on RNACStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
RNAC · as of the Nov 20 close · updated each morning
Downtrend
The stock is 6% below its 20 day and 12% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the Pivot at $6.12, and the nearest resistance the Pivot R1 at $6.34.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 7.7%/day
Key levels
$11.0052 week high+79.2%
$7.91100 day average+28.8%
$7.60200 day average+23.8%
$6.8850 day average+12.1%
$6.71Swing high (Oct 21)+9.3%
$6.5320 day average+6.4%
$6.34Pivot R1+3.3%
$6.14Last close
$6.12Pivot−0.3%
$6.07Swing low (Oct 26)−1.1%
$5.91Pivot S1−3.7%
$5.6052 week low−8.8%
Indicators
RSI (14)
42.44
Middle of its range
Neutral
MACD
-0.22
Below its signal line
Bearish
Stochastic
13.6
Near the bottom of its range
Oversold
ADX (14)
13.0
No clear trend
Williams %R
-83.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-91.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−18.5%
Change over 10 sessions
Bearish
ATR (14)
$0.47
Typical daily range, 7.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 20.2%/day
Key levels
$11.0052 week high+79.2%
$7.91100 day average+28.8%
$7.60200 day average+23.8%
$6.8850 day average+12.1%
$6.71Swing high (Oct 21)+9.3%
$6.5320 day average+6.4%
$6.34Pivot R1+3.3%
$6.14Last close
$6.12Pivot−0.3%
$6.07Swing low (Oct 26)−1.1%
$5.91Pivot S1−3.7%
$5.6052 week low−8.8%
Indicators
RSI (14)
41.49
Middle of its range
Neutral
MACD
-0.47
Below its signal line
Bearish
Stochastic
15.0
Near the bottom of its range
Oversold
ADX (14)
12.8
No clear trend
Williams %R
-93.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-121.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−25.0%
Change over 10 sessions
Bearish
ATR (14)
$1.24
Typical daily range, 20.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNAC
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RNAC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow RNAC usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for RNACHow many large options trades hit RNAC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in RNAC in the last 90 days.
From SEC Form 4 filings by RNAC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNAC is in one of them and how their past RNAC trades turned out.
Cartesian Therapeutics is a biotechnology company based in Frederick, Maryland, that is developing cell therapies for autoimmune diseases. Its approach uses mRNA to deliver a chimeric antigen receptor into a patient's own immune cells, which are then returned to the patient for outpatient treatment. Its lead product candidate, Descartes-08, is in clinical development for myasthenia gravis and certain myositis conditions. The company's target customers are patients with these conditions, and its products are not yet approved for sale.